法律诉讼概况 - Gross Law Firm向在2025年5月7日至2025年8月5日期间购买LifeMD公司股票的股东发出集体诉讼通知 [1][3] - 诉讼指控被告在该期间内发布了重大虚假和/或误导性陈述，未能披露相关信息 [3] - 股东需在2025年10月25日前登记参与此集体诉讼 [4] 具体指控内容 - 指控被告严重夸大LifeMD的竞争地位 [3] - 指控被告在提高公司2025年业绩指引时存在鲁莽行为，未恰当核算其RexMD业务部门不断增长的客户获取成本 [3] - 指控被告未恰当核算与销售肥胖治疗药物相关的客户获取成本，这些药物包括Wegovy和Zepbound [3] - 因此，被告关于公司业务、运营和前景的陈述在所有相关时间点均存在重大虚假和误导性及/或缺乏合理依据 [3]

SAN FRANCISCO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- A new federal securities fraud class action lawsuit has been filed against LifeMD, Inc. (NASDAQ: LFMD) and its executives. The suit alleges the telehealth company presented a misleadingly optimistic picture of its financial health and growth, ultimately resulting in a dramatic stock price decline in August. The action was filed in the Eastern District of New York. The lawsuit, Johnston v. LifeMD, Inc., focuses on the period between May 7, 2025, and August 5, ...

人工智能在医疗行业的转型作用 - 人工智能正在以类似30年前互联网采用的方式改变世界 尤其对医疗行业产生重大变革[1] - 生成式和代理型人工智能帮助医生和护理团队提高诊断准确性 简化行政任务 并降低职业倦怠风险[2] - 93%的医生经常感到倦怠 随着人口老龄化加剧供需失衡 人工智能有助于弥合效率与个性化护理之间的差距[2] Hims & Hers Health (HIMS) 投资分析 - 作为远程医疗公司 HIMS在2025年表现优异 年内上涨121% 过去30天上涨29%[4] - 公司利用人工智能简化行政任务 包括分诊患者问题 自动化随访提醒和简化处方续订流程[5] - 股价现报53.86美元 较2月历史高点下跌约21% 两次在65美元附近遇到阻力 交易量高显示短线交易者主导价格[6] - Canaccord Genuity集团于9月12日重申买入评级 目标价68美元 分析师共识评级为持有[7] Tempus AI (TEM) 投资分析 - 公司应用人工智能和机器学习处理基因组 临床和分子数据 推动精准医疗发展[8] - 专注于肿瘤学领域 AI工具帮助医生定制癌症治疗方案 预测结果并识别实时临床试验机会[9] - 全球前20大制药公司中有19家使用Tempus数据进行药物发现 9月获得FDA 510(k)批准RNA测序设备xR IVD[10] - 2025年股价上涨128% 过去三个月上涨17% 空头兴趣超过25% 在89美元历史高点附近显示阻力[11] Boston Scientific (BSX) 投资分析 - 医疗设备公司利用人工智能简化数据处理需求 数字健康解决方案提升性能和临床结果[13] - 近期催化剂是FDA批准FARAPULSE脉冲场消融系统扩大适用范围 治疗近6000万人的特定心房颤动[14] - 2025年股价上涨约17% 与标普500指数表现基本一致 但难以突破52周高点[15] - 尽管分析师给予买入评级 但顶级研究分析师认为其他五只股票更具投资价值[16]

YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY). The new fund aims to provide current income by utilizing options-based strategies related to Hims & Hers Health Inc (NYSE: HIMS), a prominent consumer health and wellness business.HIMS stock is showing exceptional strength. See if it is worth your attention here.Unlike other equity ETFs, HIYY does not actually invest in Hims & Hers shares. Instead, t ...

Las Vegas, NV, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide Mesquite, NV — September 26, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP today announced that its subsidiary PrestoDoctor, a leading telemedicine platform for medical cannabis evaluations, is expanding services to Connecticut. With this addition, PrestoDoctor now operates in 19 states across the United States, further extending the Company’s decade-long track record of helping patients a ...

Las Vegas, NV, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Cannabis Evaluations to Connecticut, Now Operating in 19 States NationwideMesquite, NV — September 26, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP today announced that its subsidiary PrestoDoctor, a leading telemedicine platform for medical cannabis evaluations, is expanding services to Connecticut. With this addition, PrestoDoctor now operates in 19 states across the United States, further extending the Company's decade-long track record of helping patients acc ...

Now Operating in 19 States NationwideLas Vegas, NV, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide Mesquite, NV — September 26, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP today announced that its subsidiary PrestoDoctor, a leading telemedicine platform for medical cannabis evaluations, is expanding services to Connecticut. With this addition, PrestoDoctor now operates in 19 states across the United States, further extending the Company’s decade- ...

诉讼概况 - 针对远程医疗公司LifeMD提起新的联邦证券欺诈集体诉讼，指控公司及其高管向投资者提供关于其财务健康状况和增长前景的误导性信息 [1] - 诉讼案件名称为Johnston v LifeMD Inc，聚焦于2025年5月7日至2025年8月5日期间 [5] 指控内容 - 指控公司在2025年5月6日发布第一季度业绩并上调全年营收和调整后EBITDA指引时，做出了虚假和误导性陈述 [5] - 指控公司乐观的前景展望是虚假的，其引用的虚拟肥胖护理领域“定义类别的竞争护城河”以及RexMD品牌的强劲表现，未能如实反映关键的业务挑战 [5] - 指控公司当时未向投资者披露其RexMD部门客户获取成本上升以及体重管理业务退款率高于预期的问题 [6] 股价影响 - 指控的欺骗行为在2025年8月5日公司公布第二季度业绩时暴露，其营收和每股收益未达预期，并随后大幅下调了全年业绩指引 [7] - 在业绩电话会上，管理层将原因归咎于RexMD业务的“暂时性升高的客户获取成本”以及体重管理服务的患者退款问题 [7] - 在业绩公布后的第二天，LifeMD股价暴跌超过44% [7] 调查与背景 - 原告权利律师事务所Hagens Berman正在调查相关指控，调查重点在于LifeMD是否知晓但未能披露关键运营问题 [10] - Hagens Berman在此领域已为客户追回超过29亿美元 [13]

LifeMD (NASDAQ: LFMD ) is a smaller player in telehealth. LifeMD defines itself as a "direct-to-patient telehealth company providing a high-quality, cost-effective, and convenient way to access comprehensive, virtual, and in-home healthcare." Translation: LifeMD lets you see a doctor without leaving your house.I am a software developer by trade who focuses on finding value in the market wherever it may lie. I'm looking mainly in small caps for opportunities that provide asymmetric upside. I'm also intereste ...

LifeMD (NASDAQ: LFMD ) is a smaller player in telehealth. LifeMD defines itself as a "direct-to-patient telehealth company providing a high-quality, cost-effective, and convenient way to access comprehensive, virtual, and in-home healthcare." Translation: LifeMD lets you see a doctor without leaving your house.I am a software developer by trade who focuses on finding value in the market wherever it may lie. I'm looking mainly in small caps for opportunities that provide asymmetric upside. I'm also intereste ...